[1] 曾小峰,朱松林,谭爱春,等.我国类风湿关节炎疾病负担和生存质量研究的系统评价[J].中国循证医学杂志, 2013, 13(3):300-307. [2] 陈俊伟,李小峰,张莉芸,等.短期益赛普与甲氨蝶呤环磷酰胺联合治疗类风湿关节炎的临床研究[J].中华风湿病学杂志, 2008,12(7):480-483. [3] Felson D T, Anderson J J, Boers M, et al. American college of rheumatology.Preliminary definition of improvement in rheumatoid arthritis[J]. Arthitis Rheum, 1995, 38(6):727-735. [4] 汪珊.生物制剂益赛普联合甲氨蝶呤治疗难治性类风湿关节炎的疗效观察[J].重庆医学, 2013, 42(26):3100-3101,3104. [5] 荆丹清,尹士男,白桦,等.益赛普治疗类风湿关节炎疗效观察及安全性分析[J].中国骨与关节杂志, 2012, (5):480-483. [6] 孙晓云,苏茵,任丽敏,等. rhRNFR:Fc对类风湿关节炎患者血清中致炎及抗炎因子的影响[J].中华风湿病学杂志, 2006, 10(4): 209-212. [7] Paul E, Breedveld F C, Stephen H, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial.[J]. Lancet, 2008, 372(9636):375-382. [8] Smolen J S, Landewé R, Breedveld F C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update[J]. Ann Rheum Dis, 2014, 73(3):492-509. [9] Kekow J, Moots R J, Emery P, et al. Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: The COMET trial[J]. Annals of the Rheumatic Diseases, 2010, 69(1):222-225. |